Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Apr 25;2(1):72-76.
doi: 10.1159/000214838.

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report

Joan Manel Gasent Blesa  1 , Vicente Alberola Candel
Affiliations
Case Reports

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report

Joan Manel Gasent Blesa et al. Case Rep Oncol. .

Abstract

Metastatic prostate cancer is an incurable disease. After a period of hormone sensitivity that allows for the use of antiandrogens, the disease invariably progresses to a situation of androgen-independent growth, which deserves the consideration or the use of chemotherapy. As many of these patients are elderly and fragile, treatment with chemotherapy is challenging. Therefore, new drugs are required. Preclinical evidence supports the role of estrogen receptor (ER) signaling in prostate cancer. In this paper, we report the first published evidence of PSA control in a patient with metastatic prostate cancer treated with fulvestrant acetate.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PSA level dynamics.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7:211–216. - PubMed
    1. Loberg RD, Fielhauer JR, Pienta BA, et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology. 2003;62(suppl 1):128–133. - PubMed
    1. Taplin ME, Ho SM. Clinical review 134: the endocrinology of prostate cancer. J Clin Endocrinol Metab. 2001;86:3467–3477. - PubMed
    1. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995;87:746–750. - PubMed
    1. Nuttall ME, Pendrak I, Emery JG, Nadeau DP, et al. Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents. Cancer Chemother Pharmacol. 2001;47:437–443. - PubMed

Publication types